尿路上皮癌に対し集学的治療で完全奏効を得られた リンチ症候群の-例.

The patient was an 75-year-old man with Lynch syndrome as an underlying disease. He had undergone multiple surgeries for gastric, colorectal, and small intestine cancers. In February 201X, the patient visited our hospital with gross hematuria. Cystoscopy revealed multiple neoplastic lesions in the bladder. Transurethral surgery for malignant bladder tumor was performed, and the patient was diagnosed with urothelial carcinoma. After that, recurrence was observed in the left ureter, and left nephroureterectomy was performed in November 201X. From May 201X+1, pembrolizumab was administered for about 2 years because of the suspicion of recurrence of urothelial carcinoma due to thickening of the left bladder wall and suspicion of urothelial cancer. In May 201X+3, CT examination showed improvement in the wall thickening on the left side wall, and the patient was diagnosed with CR. Accordingly, the administration of pembrolizumab was discontinued. However, thickening of the left wall was confirmed again, and recurrence was suspected again. Six courses of GC therapy were performed, and the thickening improved. Pathological results showed no obvious malignant findings. Six months have passed without recurrence. In this paper, we report a case of urothelial carcinoma in a patient with Lynch syndrome as an underlying disease who achieved a complete response to multidisciplinary therapy. [ABSTRACT FROM AUTHOR]